ReviewArchives of pharmacal research2021
Skin barrier dysfunction and filaggrin.
Review in Archives of pharmacal research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 139 citations in OpenAlex.
- Application of Antioxidant Mixture Prevents Cutaneous "Oxinflammaging" in Subjects Exposed to Particulate Matter.Journal of cosmetic dermatology · 2025Trial
- Multi-omics analysis of transcriptomics and proteomics to provide mechanistic insights into the effects of camellia oil in alleviating xerosis cutis.Biochemistry and biophysics reports · 2026Article
- Protective effects of three natural extracts on ovalbumin-induced intestinal and skin damage in felines via the gut-skin axis: AnBiochemistry and biophysics reports · 2026Article
- From Barrier Disruption and Immune Dysregulation to Targeted Therapies in Atopic Dermatitis.Clinical reviews in allergy & immunology · 2026Review
- Potential Supportive Effects of AP Collagen Peptides on Skin Hydration in a Mouse Model of Oxazolone-Induced Atopic Dermatitis.Journal of microbiology and biotechnology · 2026Article
- Indole-2-carboxylic Acid Nanoemulsions: A Novel Approach for Topical Cosmeceuticals with Antioxidant Properties in Human Skin Models.ACS omega · 2026Article
- Primary atopic disorders: Monogenic insights into immunity.Journal of human immunity · 2026Review
- Single-cell transcriptomic analysis identifies a MIF-driven keratinocyte-macrophage-Th2 axis as a key inflammatory circuit in atopic dermatitis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Article
- Epidermal Permeability Barrier Dysfunction Influences Acute and Chronic Skin Responses to UVA and UVB Radiation.Photodermatology, photoimmunology & photomedicine · 2026Article
- Investigation of the effects of a Kiperin Bromelain & Papain complex in normal colon, mammary, and skin cells.Scientific reports · 2026Article
- Cold atmospheric plasma ameliorating skin barrier in chronic kidney disease.NPJ Regenerative medicine · 2026Article
- Plant extract mixture shows anti-inflammatory and barrier-strengthening effects and activates aryl hydrocarbon receptor in a 2D psoriasis model.Scientific reports · 2026Article
- Quinoa bioester application shifts human skin proteome toward molecular profiles associated with younger age.Communications biology · 2026Observational
- Developing and Evaluating Stable Microemulsion Systems for Potential Intranasal and Transdermal Application of Omeprazole.AAPS PharmSciTech · 2026Article
- Regulation of Keratin Chemical Modifications: Potential Molecular Mechanisms in Proliferative Diseases.International journal of molecular sciences · 2026Review
- Molecular insights into the role of vitamin D in atopic dermatitis: pathogenesis, diagnosis, and emerging therapies.Frontiers in immunology · 2026Review
- Innovative research on predicting skin flaps necrosis through quantification of the USP4/TNFAIP2 regulated 'M1 macrophages-Tregs axis' via skin barrier monitoring technology.Burns & trauma · 2026Article
- Immunological and molecular biomarkers in skin allergy therapy: monitoring inflammation, barrier function, and treatment response.Postepy dermatologii i alergologii · 2026Review
- Fermentation-Induced Changes in Phytochemical Composition and Pharmacological Activities ofDrug design, development and therapy · 2026Review
- Skin phenotype diversity across populations: from skin morphology to molecular phenotype.Frontiers in medicine · 2026Review
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Skin barrier dysfunction caused by endogenous or exogenous factors can lead to various disorders such as xerosis cutis, ichthyoses, and atopic dermatitis. Filaggrin is a pivotal structural protein of the stratum corneum (SC) and provides natural moisturizing factors that play a role in skin barrier functions. Filaggrin aggregates keratin filaments, resulting in the formation of a keratin network, which binds cornified envelopes and collapse keratinocytes to flattened corneocytes. This complex network contributes to the physical strength of the skin. Filaggrin is degraded by caspase-14, calpain 1, and bleomycin hydrolases into amino acids and amino acid metabolites such as trans-urocanic acid and pyrrolidone carboxylic acid, which are pivotal natural moisturizing factors in the SC. Accordingly, filaggrin is important for the pathophysiology of skin barrier disorders, and its deficiency or dysfunction leads to a variety of skin disorders. Here, the roles and biology of filaggrin, related skin diseases, and a therapeutic strategy targeting filaggrin are reviewed. In addition, several drug candidates of different mode of actions targeting filaggrin, along with their clinical efficacy, are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.